Article
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 13 Oct 2023
Grisham Rachel N, Vergote Ignace, Banerjee Susana, Drill Esther, Kalbacher Elsa, Mirza Mansoor Raza, Romero Ignacio, Vuylsteke Peter, Coleman Robert L, Hilpert Felix, Oza Amit M, Westermann Anneke, Oehler Martin K, Pignata Sandro, Aghajanian Carol, Colombo Nicoletta, Cibula David, Moore Kathleen N, Del Campo Josep M, Berger Regina, Marth Christian, Sehouli Jalid, O'Malley David M, Churruca Cristina, Kristensen Gunnar, Clamp Andrew, Farley John, Iyer Gopa, Ray-Coquard Isabelle, Monk Bradley J
Abstract excerpt
PURPOSE: We present the results of a post hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874). PATIENTS AND METHODS: Mutation/copy-number analysis was performed on tissue obtained pre-randomization. The Kaplan-Meier method was used to estimate progression-free survival (PFS). Unbiased univariate analysis, Cox regression, and binary logistic regression were used to test associations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.